26.90

0.44% -0.12

Ultragenyx Pharmaceutical Inc (RARE)

Overview News Price History Option Chain Financials Why RARE Down? Discussions Forecast Stock Split

Ultragenyx Pharmaceutical Inc stock is traded at $26.90, with a volume of 1.50M. It is down -0.44% in the last 24 hours and down -7.59% over the past month. Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. The company identifies, acquires, develops, and commercializes novel products for the treatment of serious, rare, and ultra-rare diseases, with a focus on debilitating genetic conditions. Its medicine portfolio includes Crysvita, Dojolvi, and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients aged one year and older. Mepsevii is indicated for pediatric and adult patients for the treatment of Mucopolysaccharidosis VII. The company operates across North America, Latin America, Europe, the Middle East and Africa, and Asia-Pacific, with the majority of its revenue generated from North America.

Previous Close:

$27.02

Open:

$27.32

24h Volume:

1.50M

Relative Volume:

0.71

Market Cap:

$2.65B

Revenue:

$669.43M

Net Income/Loss:

$-609.36M

P/E Ratio:

-4.4054

EPS:

-6.1061

Net Cash Flow:

$-507.20M

1W Performance:

-8.13%

1M Performance:

-7.59%

6M Performance:

+11.11%

1Y Performance:

-1.47%

1-Day Range:

$26.50

$27.48

1-Week Range:

$26.50

$30.03

52-Week Range:

$18.29

$39.89

Ultragenyx Pharmaceutical Inc Stock (RARE) Company Profile

Name

Ultragenyx Pharmaceutical Inc

Sector

Healthcare (1071)

Industry

Biotechnology (598)

Phone

415-483-8800

Address

60 LEVERONI COURT, NOVATO, CA

Employee

1,371

Twitter

Next Earnings Date

2026-08-04

Latest SEC Filings

RARE's Discussions on Twitter

Compare RARE vs VRTX, REGN, ARGX, RVMD, ALNY

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
RARE Ultragenyx Pharmaceutical Inc	26.90	2.65B	669.43M	-609.36M	-507.20M	-6.1061
VRTX Vertex Pharmaceuticals Inc	477.36	121.16B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	656.01	68.78B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	918.22	57.44B	4.16B	1.29B	734.26M	19.58
RVMD Revolution Medicines Inc	189.23	40.23B	742.00K	-1.37B	-1.07B	-7.0731
ALNY Alnylam Pharmaceuticals Inc	271.77	36.28B	4.29B	577.22M	641.34M	4.2086

Ultragenyx Pharmaceutical Inc Stock (RARE) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Mar-24-26	Downgrade	Goldman	Buy → Neutral
Oct-20-25	Initiated	Wells Fargo	Overweight
Jul-28-25	Resumed	H.C. Wainwright	Buy
May-28-25	Initiated	William Blair	Outperform
Jun-06-24	Upgrade	Goldman	Neutral → Buy
Apr-22-24	Initiated	RBC Capital Mkts	Outperform
Dec-08-23	Initiated	Wells Fargo	Overweight
Jun-14-23	Resumed	Credit Suisse	Outperform
Jun-06-23	Upgrade	Evercore ISI	In-line → Outperform
Apr-26-23	Initiated	Cantor Fitzgerald	Overweight
Jan-18-23	Resumed	Canaccord Genuity	Buy
Dec-30-22	Resumed	H.C. Wainwright	Buy
Nov-03-22	Upgrade	Robert W. Baird	Neutral → Outperform
Oct-13-22	Upgrade	Guggenheim	Neutral → Buy
Aug-01-22	Downgrade	Evercore ISI	Outperform → In-line
Mar-16-22	Upgrade	Credit Suisse	Neutral → Outperform
Feb-11-22	Upgrade	JP Morgan	Neutral → Overweight
Sep-30-21	Initiated	H.C. Wainwright	Buy
Aug-19-21	Initiated	UBS	Sell
Jul-15-21	Initiated	Guggenheim	Neutral
Jun-29-21	Upgrade	BofA Securities	Neutral → Buy
Jun-04-21	Resumed	Robert W. Baird	Neutral
May-06-21	Upgrade	Citigroup	Neutral → Buy
May-06-21	Upgrade	Evercore ISI	In-line → Outperform
Apr-26-21	Resumed	Credit Suisse	Neutral
Mar-02-21	Resumed	Stifel	Buy
Feb-12-21	Downgrade	JP Morgan	Overweight → Neutral
Dec-07-20	Downgrade	Wedbush	Outperform → Neutral
Nov-24-20	Resumed	Evercore ISI	In-line
Nov-12-20	Downgrade	BofA Securities	Buy → Neutral
Aug-02-19	Resumed	Wedbush	Outperform
Mar-27-19	Upgrade	Morgan Stanley	Equal-Weight → Overweight
Feb-22-19	Resumed	Raymond James	Outperform
Jan-02-19	Downgrade	Raymond James	Outperform → Mkt Perform
Nov-08-18	Upgrade	Citigroup	Sell → Neutral
Sep-10-18	Initiated	Morgan Stanley	Equal-Weight
Jun-21-18	Downgrade	Credit Suisse	Outperform → Neutral
May-11-18	Upgrade	Barclays	Equal Weight → Overweight
May-10-18	Initiated	Goldman	Neutral
Apr-18-18	Upgrade	SunTrust	Hold → Buy
Mar-22-18	Resumed	Piper Jaffray	Overweight
Feb-21-18	Reiterated	Stifel	Buy
Jan-22-18	Upgrade	Evercore ISI	In-line → Outperform
Jan-18-18	Initiated	Credit Suisse	Outperform
Dec-05-17	Reiterated	Barclays	Equal Weight
Dec-04-17	Upgrade	Jefferies	Hold → Buy
Sep-14-17	Upgrade	Wedbush	Neutral → Outperform

View All

Ultragenyx Pharmaceutical Inc Stock (RARE) Latest News

Jul 24, 2026

Ultragenyx New Hires Get Stock Awards, 25% Vests Yearly - Stock Titan

Jul 24, 2026

Jul 22, 2026

RARE Stock Slumps On Multiple Wall Street Price Target Slashes, Clinical Pipeline Uncertainty - Stocktwits

Jul 22, 2026

Jul 21, 2026

Ultragenyx Pharmaceutical Stock Slides 20% With A 9-Day Losing Spree - Trefis

Jul 21, 2026

Ultragenyx Pharmaceutical Stock Extends A 9-Day Losing Streak To A 20% Loss - Trefis

Jul 21, 2026

Jul 20, 2026

(RARE) Movement as an Input in Quant Signal Sets - Stock Traders Daily

Jul 20, 2026

RARE stock reflects Ultragenyx cash position and recent clinical progress - AD HOC NEWS

Jul 20, 2026

Jul 18, 2026

Ultragenyx Pharmaceutical (RARE) On Rare Disease Growth Narrative And Why Valuation Is Back In Focus - Sahm

Jul 18, 2026

Jul 17, 2026

Ultragenyx Pharmaceutical Currently Down Eight Consecutive Days, on Pace for Longest Losing Streak Since December 2024 -- Data Talk - Moomoo

Jul 17, 2026

RARE stock rises after Ultragenyx reports strong Crysvita revenue growth and narrows quarterly loss - Ad-hoc-news.de

Jul 17, 2026

Jul 15, 2026

RARE Stock Edges Up On Priority Review For Gene Therapy In Rare Metabolic Disorder - Stocktwits

Jul 15, 2026

Law firm probes Ultragenyx officers for alleged false statements on drug trial results - Pluang

Jul 15, 2026

Johnson Fistel, PLLP Investigates Claims on Behalf of - GlobeNewswire

Jul 15, 2026

BofA Securities Maintains Ultragenyx Pharmaceutical(RARE.US) With Buy Rating, Announces Target Price $48 - Moomoo

Jul 15, 2026

Jul 13, 2026

Wedbush Raises Price Target on Ultragenyx Pharmaceutical to $30 From $26, Keeps Neutral Rating - Moomoo

Jul 13, 2026

Jul 09, 2026

Ultragenyx Pharmaceutical (RARE) Is Up 7.4% After Index Migration To Russell 2000 And Value BenchmarksHas The Bull Case Changed? - Sahm

Jul 09, 2026

Jul 08, 2026

Ultragenyx releases 2025 impact report on rare disease work By Investing.com - Investing.com South Africa

Jul 08, 2026

Ultragenyx releases 2025 impact report on rare disease work - Investing.com

Jul 08, 2026

Ultragenyx Releases 2025 Impact Report Emphasizing Commitment to Rare Disease Patients, Innovation, and Global Impact - The Manila Times

Jul 08, 2026

Ultragenyx Releases 2025 Impact Report Highlighting Progress in Rare Disease Therapies, Patient Access and Sustainability - Quiver Quantitative

Jul 08, 2026

Ultragenyx Releases 2025 Impact Report Emphasizing - GlobeNewswire

Jul 08, 2026

Ultragenyx says five rare-disease programs reached pivotal trials in 2025 - Stock Titan

Jul 08, 2026

Jul 07, 2026

RBC Capital Adjusts Ultragenyx Pharmaceutical Price Target to $40 From $35, Maintains Outperform Rating - Moomoo

Jul 07, 2026

RBC Capital Maintains Ultragenyx Pharmaceutical(RARE.US) With Buy Rating, Raises Target Price to $40 - Moomoo

Jul 07, 2026

Jul 06, 2026

Ultragenyx CFO Howard Horn sells $155,644 in company shares By Investing.com - Investing.com South Africa

Jul 06, 2026

Form 144 ULTRAGENYX PHARMACEUTICAL INC. For: 1 July By Investing.com - Investing.com Canada

Jul 01, 2026

RARE (NASDAQ: RARE) affiliate reports insider sales and scheduled awards - Stock Titan

Jul 01, 2026

Jun 30, 2026

RARE DEADLINE: ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Ultrage - The National Law Review

Jun 30, 2026